COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Rosiglitazone Versus Theophylline in Asthmatic Smokers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00119496
Recruitment Status : Completed
First Posted : July 13, 2005
Last Update Posted : January 27, 2010
Chest, Heart and Stroke Association Scotland
Chief Scientist Office of the Scottish Government
Information provided by:
University of Glasgow

Brief Summary:

Asthmatic smokers display a blunted response to both inhaled and oral corticosteroid treatments and are at increased risk for exacerbations and near fatal asthma. The prevalence of smoking in asthmatics runs between 20-30%. Therefore, new, more efficacious treatments are required.

Recent work has demonstrated a mechanism which may explain steroid resistance. A commonly used drug called theophylline can reverse this steroid resistance in laboratory studies. Another commonly used drug, rosiglitazone can reverse smoking induced lung inflammation in laboratory studies.

The investigators aim to study the effects of these drugs on smoking asthmatics' lung function and other parameters including quality of life and asthma control.

Condition or disease Intervention/treatment Phase
Asthma Drug: rosiglitazone Drug: theophylline Drug: beclomethasone Drug: inhaled beclomethasone and oral theophylline Phase 2 Phase 3

Detailed Description:

Smoking asthmatics have chronic pulmonary inflammation that is relatively steroid resistant. PPAR agonists (of which rosiglitazone is one example) have been shown to reduce several markers of inflammation in humans and in smoking animal models.

This clinical study will use smoking asthmatics as a human model of smoke-induced steroid-insensitive airway inflammation to evaluate both efficacy of rosiglitazone as an anti-inflammatory drug as well as the effect of low doses of theophylline on the response to low-dose inhaled corticosteroid (LD ICS).

Mild or moderate (as per GINA guidelines) persistent-asthmatic smokers will be randomised into this study after a 4-week washout period during which they will be withdrawn from inhaled corticosteroids (ICS). Subjects will then receive one of four treatments for 28 days: rosiglitazone, LD ICS, theophylline, or LD ICS plus theophylline.

The effects of rosiglitazone and LD ICS on pulmonary function will be compared as a primary objective. In addition, effects of theophylline plus LD ICS will be compared against theophylline and LD ICS separately. Both pulmonary anti-inflammatory and systemic anti-inflammatory activity will also be investigated.

Subjects will have baseline assessments of pulmonary function, biomarkers of systemic inflammation, sputum, exhaled breath biomarkers, asthma control questionnaires and safety parameters. Following 28 days of treatment, these parameters will all be reassessed in all subjects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 79 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Clinical Study to Investigate the Effect of Rosiglitazone, Theophylline and Inhaled Corticosteroid, Inflammation and Pulmonary Function in Asthmatic Smokers
Study Start Date : July 2005
Actual Study Completion Date : June 2007

Arm Intervention/treatment
Active Comparator: Group 1
Inhaled beclomethasone (400mcg/day)
Drug: beclomethasone
inhaled beclomethasone, 200mcg bd
Other Name: Qvar

Active Comparator: Arm 2
Drug: rosiglitazone
oral tablet, 4mg bd for 4 weeks
Other Name: Rosiglitazone Maleate, Avandia

Active Comparator: Arm3
Oral theophylline
Drug: theophylline
Oral theophylline, 200mg bd
Other Name: uniphyllin

Active Comparator: Arm 4
Oral theophylline and inhaled beclomethasone
Drug: inhaled beclomethasone and oral theophylline
inhaled beclomethasone (400mcg/day), oral theophylline (400mg/day)
Other Name: Qvar and uniphyllin

Primary Outcome Measures :
  1. Comparison of pre-bronchodilator (FEV1) at 28 days between rosiglitazone and LD ICS treatment groups. [ Time Frame: 28 days ]

Secondary Outcome Measures :
  1. Rosiglitazone vs LD ICS on other endpoints of pulmonary function in smoking asthmatics. [ Time Frame: 28 days ]
  2. Theophylline plus LD ICS vs LD ICS on pulmonary function in smoking asthmatics. [ Time Frame: 28 days ]
  3. Theophylline plus LD ICS vs theophylline on pulmonary function in smoking asthmatics. [ Time Frame: 28 days ]
  4. Safety and tolerability of rosiglitazone, LD ICS, theophylline and theophylline plus LD ICS in smoking asthmatics. [ Time Frame: 28 days ]
  5. To assess the effects in smoking asthmatics of rosiglitazone, LD ICS, theophylline and theophylline plus LD ICS on asthma control using the ACQ (Juniper et al, 1999). [ Time Frame: 28 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or females between 18 and 60 years of age (inclusive).
  • Clinical diagnosis of mild or moderate persistent asthma in accordance with the Global Initiative for Asthma (GINA) criteria
  • Have had a history of asthma for a minimum of 6 months prior to entry into the study
  • Subjects must be current cigarette smokers with a minimum five-pack-year smoking history
  • Baseline FEV1 that is greater than 50% predicted; and reversibility of 12% or more at screening, washout or randomisation.
  • Capable of providing signed written informed consent and complying with all the specified study procedures.

Exclusion Criteria:

  • Asthma exacerbation or a respiratory tract infection within four weeks of screening.
  • Type 1 or type 2 diabetes mellitus.
  • Women who are lactating, pregnant, or planning to become pregnant.
  • Clinically significant renal or hepatic laboratory values (e.g. AST/ALT/total bilirubin/AP > 2.5 times normal values).
  • Anaemia (< 11 g/dL for males or < 10 g/dL for females)
  • Contraindications to treatment as outlined in any of the product labels
  • Prior history of severe oedema or serious fluid related event (e.g., heart failure) associated with any TZD
  • The subject has a history of significant hypersensitivity to study drugs
  • Presence of unstable or severe angina or congestive heart failure (NYHA class III/IV) or evidence or history of known congestive heart failure (NYHA class I-IV) or an abnormal electrocardiogram (ECG), as determined by the Investigator, or subjects who have had new cardiac events (such as MI, new CHF, PTCA, CABG) within 6 months of screening.
  • History or suspicion of current drug abuse or alcohol abuse within the last 6 months.
  • History suggestive of active infection or non-asthma lung pathology
  • Clinically significant renal disease, metabolic syndrome, cirrhosis (Child-Pugh Class B/C), hypertension or any other clinically significant cardiovascular, neurological, endocrine, or haematological abnormalities that are uncontrolled on permitted therapy.
  • Risk factors for human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection at Screening (Visit 1)
  • Subjects who are morbidly obese, defined as having a body mass index (BMI) > 40 kg/m2
  • Unable to perform spirometry
  • Subjects who require treatment with any of the following asthma medications from Screening (Visit 1) until study completion:

    • Inhaled cromolyn sodium or nedocromil;
    • Ipratropium bromide;
    • Xanthines (theophylline preparations);
    • Leukotriene modifiers;
    • Long-acting inhaled beta2-agonists (salmeterol, formoterol);
    • Oral beta2-agonists.
  • Treatment with oral, intravenous or intra-articular corticosteroids within 6 weeks of Screening or thereafter.
  • Subjects who have been taking in excess of 1000 μg daily of beclomethasone (or equivalent) within 6 weeks of Screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00119496

Layout table for location information
United Kingdom
Asthma Research Group, Gartnavel General Hospital
Glasgow, Scotland, United Kingdom, G12 0YN
Sponsors and Collaborators
University of Glasgow
Chest, Heart and Stroke Association Scotland
Chief Scientist Office of the Scottish Government
Layout table for investigator information
Principal Investigator: Neil C Thomson, MD University of Glasgow
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00119496    
Other Study ID Numbers: RES104033
2004-004247-22 EUDRACT
First Posted: July 13, 2005    Key Record Dates
Last Update Posted: January 27, 2010
Last Verified: November 2007
Keywords provided by University of Glasgow:
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hypoglycemic Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Anti-Asthmatic Agents
Respiratory System Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Phosphodiesterase Inhibitors
Vasodilator Agents
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents